期刊文献+

外泌体在恶病质炎症反应中的作用及机制研究进展 被引量:1

Hazard and mediation mechanism of exosomes in the cachexia inflammatory response
下载PDF
导出
摘要 恶病质是一种严重的慢性消耗性状态,是恶性肿瘤、终末期心力衰竭等疾病常见的并发症。恶病质进程中异常的炎症反应在肌肉、脂肪丢失及肿瘤增殖转移中发挥重要作用。近年研究发现,外泌体内携带的微小核糖核酸(microRNA)、长链非编码核糖核酸(lncRNA)等成分可通过介导细胞间通信,激活相关信号通路,促进多种炎性因子的分泌,从而介导恶病质炎症反应,影响局部和远端炎性微环境的形成,促进肿瘤细胞增殖、转移并抑制其凋亡,加速恶病质的进展。本文对外泌体与恶病质炎症反应的关系、恶病质炎症反应的危害及外泌体通过调控Toll样受体、核因子κB(NF-KB)、CC趋化因子配体2(CCL2)等分子和通路诱发恶病质炎症反应的作用机制进行综述,旨在为预防恶病质炎症反应及减缓恶病质进展提供新的思路。 Cachexia is a serious chronic wasting syndrome,which is a common complication of cancer,end-stage heart failure and other diseases.The abnormal inflammatory response in the process of cachexia plays an important role in the loss of muscle and fat,the proliferation and metastasis of tumors.In recent years,it has been found that microRNA and long non-coding RNA(lncRNA)carried in exosomes can mediate cell-to-cell communication,activate related signaling pathway to secrete various inflammatory factors.It mediates the inflammatory response of cachexia,affects the formation of local and distal inflammatory microenvironment,promotes tumor cell proliferation,metastasis and inhibits its apoptosis,thereby accelerating the progression of cachexia.This review mainly summarizes the relationship between exosome and cachexia inflammation response,the harm of cachexia inflammation response and the mechanism of action,and provides new ideas for preventing it and slowing down the cachexia progress.
作者 吴涛 徐圣洁 李晓 王咏 马度芳 Wu Tao;Xu Sheng-Jie;Li Xiao;Wang Yong;Ma Du-Fang(The First Clinical College,Shandong University of Traditional Chinese Medicine,Jinan,Shandong 250000,China;Department of Cardiovascular Disease,Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan,Shandong 250014,China)
出处 《解放军医学杂志》 CAS CSCD 北大核心 2023年第5期602-608,共7页 Medical Journal of Chinese People's Liberation Army
基金 国家自然科学基金(82004280,82074388)。
关键词 恶病质炎症反应 外泌体 肿瘤微环境 炎性因子 cachexia inflammation response exosome tumor microenvironment inflammatory factor
  • 相关文献

参考文献3

二级参考文献45

  • 1Galle J, Sittig D, Hanisch I, Wobus M, Wandel E, Loeffler M,Aust G. Individual cell-based models of tumor-environmentinteractions: Multiple effects of CD97 on tumor invasion. Am JPathol 2006; 169: 1802-1811 [PMID: 17071601 DOI: 10.2353/ajpath.2006.060006].
  • 2Aust G, Steinert M, Schütz A, Boltze C, Wahlbuhl M, HamannJ, Wobus M. CD97, but not its closely related EGF-TM7 familymember EMR2, is expressed on gastric, pancreatic, and esophagealcarcinomas. Am J Clin Pathol 2002; 118: 699-707 [PMID:12428789 DOI: 10.1309/A6AB-VF3F-7M88-C0EJ].
  • 3Martens GJ. Molecular biology of G-protein-coupled receptors.Prog Brain Res 1992; 92: 201-214 [PMID: 1338880 DOI: 10.1016/S0079-6123(08)61176-0].
  • 4Eichler W, Aust G, Hamann D. Characterization of an earlyactivation-dependent antigen on lymphocytes defined by themonoclonal antibody BL-Ac(F2). Scand J Immunol 1994; 39:111-115 [PMID: 8290889 DOI: 10.1111/j.1365-3083.1994.tb03348.x].
  • 5Veninga H, Becker S, Hoek RM, Wobus M, Wandel E, van derKaa J, van der Valk M, de Vos AF, Haase H, Owens B, van der PollT, van Lier RA, Verbeek JS, Aust G, Hamann J. Analysis of CD97expression and manipulation: antibody treatment but not genetargeting curtails granulocyte migration. J Immunol 2008; 181:6574-6583 [PMID: 18941248 DOI: 10.4049/jimmunol.181.9.6574].
  • 6Han SL, Xu C, Wu XL, Li JL, Liu Z, Zeng QQ. The impact ofexpressions of CD97 and its ligand CD55 at the invasion front onprognosis of rectal adenocarcinoma. Int J Colorectal Dis 2010; 25:695-702 [PMID: 20339853 DOI: 10.1007/s00384-010-0926-5].
  • 7Steinert M, Wobus M, Boltze C, Schütz A, Wahlbuhl M, Hamann J,Aust G. Expression and regulation of CD97 in colorectal carcinomacell lines and tumor tissues. Am J Pathol 2002; 161: 1657-1667[PMID: 12414513 DOI: 10.1016/S0002-9440(10)64443-4].
  • 8Aust G, Eichler W, Laue S, Lehmann I, Heldin NE, Lotz O,Scherbaum WA, Dralle H, Hoang-Vu C. CD97: a dedifferentiationmarker in human thyroid carcinomas. Cancer Res 1997; 57:1798-1806 [PMID: 9135025].
  • 9Hoang-Vu C, Bull K, Schwarz I, Krause G, Schmutzler C, AustG, K-hrle J, Dralle H. Regulation of CD97 protein in thyroidcarcinoma. J Clin Endocrinol Metab 1999; 84: 1104-1109 [PMID:10084602].
  • 10Jaspars LH, Vos W, Aust G, Van Lier RA, Hamann J. Tissuedistribution of the human CD97 EGF-TM7 receptor. TissueAntigens 2001; 57: 325-331 [PMID: 11380941 DOI: 10.1034/j.1399-0039.2001.057004325.x].

共引文献30

同被引文献26

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部